

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 3802-090-27 CIP		SERIAL NO. 10/807,449	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)				APPLICANT Karin JOOSS et al.		GROUP ART UNIT 1632-1644	
				FILING DATE March 24, 2004			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
DO	AA	5,904,920	05/1999	Dranoff et al.			
	AB	5,078,996	01/1992	Conlon, III et al.			
	AC	5,098,702	03/1992	Zimmerman et al.			
	AD	5,225,348	07/1993	Nagata et al.			
	AE	5,266,491	11/1993	Nagata et al.			
	AF	5,436,146	07/1995	Shenk et al.			
	AG	5,637,483	06/1997	Dranoff et al.			
	AH	5,665,577	09/1997	Sodroski et al.			
	AI	5,674,486	10/1997	Sobol et al.			
	AJ	5,674,704	10/1997	Goodwin et al.			
	AK	5,753,500	05/1998	Shenk et al.			
	AL	5,872,005	02/1999	Wang et al.			
	AM	5,904,920	05/1999	Dranoff et al.			
	AN	5,928,893	07/1999	Kang et al.			
	AO	5,955,331	09/1999	Danos et al.			
	AP	5,981,276	11/1999	Sodroski et al.			
	AQ	5,985,290	11/1999	Jaffee et al.			
	AR	6,033,674	03/2000	Jaffee et al.			
	AS	6,037,177	03/2000	Snyder			
	AT	6,040,183	03/2000	Ferrari et al.			
	AU	6,093,570	07/2000	Ferrari et al.			
	AV	6,210,669 B1	04/2001	Aruffo et al.			
	AW	6,303,121 B1	10/2001	Kwon			
	AX	6,350,445 B1	02/2002	Jaffee et al.			
DO	AY	6,355,779 B1	03/2002	Goodwin et al.			
EXAMINER <i>Ilia Ouspenski</i>					DATE CONSIDERED 6/18/07		

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 3802-090-27 CIP		SERIAL NO. 10/807,449	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)				APPLICANT Karin JOOSS et al.		GROUP ART UNIT 1632	
				FILING DATE March 24, 2004			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
JO	AZ	6,428,953 B1	08/2002	Naldini et al.			
	BA	6,458,934 B1	10/2002	Hong et al.			
	BB	6,464,973 B1	10/2002	Levitsky et al.			
	BC	6,506,604	01/2003	Finer et al.			
	BD						
	BE						
	BF						
	BG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	BH	WO 00/72686 A1	12/07/00	WIPO	X		
	BI	WO 98/46728 A1	10/22/98	WIPO	X		
	BJ	WO 92/05262	04/02/92	WIPO	X		
✓	BK	WO99/38954	08/05/99	WIPO	X		
	BL						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	BM	Aoki et al., "Expression of Murine Interleukin 7 in a Murine Glioma Cell Line Results in Reduced Tumorigenicity <i>in vivo</i> ", Proc. Natl. Acad. Sci. USA, 89:3850-3854 (1992).					
	BN	Cantrell et al., "Cloning, Sequence, and Expression of a Human Granulocyte/Macrophage Colony-Stimulating Factor", Proc. Nat'l Acad. Sci. USA, 82:6250-6254 (1985).					
	BO	Chang, et al., "Immunogenetic Therapy of Human Melanoma Utilizing Autologous Tumor Cells Transduced to Secrete Granulocyte-Macrophage Colony-Stimulating Factor", Human Gene Therapy, 11:839-850 (2000).					
	BP	Cryer, et al., "Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs", Am. J. Med., 104: 413-421 (1998).					
JO	BQ	Darrow, et al., "The Role of HLA Class I Antigens in Recognition of Melanoma Cells By Tumor-Specific Cytotoxic T Lymphocytes", J. Immunol., 142(9):3329-3335 (1989).					
EXAMINER					DATE CONSIDERED		
Jian Owspecki					6/18/06		
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

✓ Only FOR received.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 3802-090-27 CIP	SERIAL NO. 10/807,449
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Karin JOOSS et al.		GROUP ART UNIT 1632	
		FILING DATE March 24, 2004			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
JO	BR	Dranoff, et al., "Vaccination With Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity", Proc. Nat'l Acad. Sci. USA, 90:3539-3543 (1993).			
	BS	Dummer, R., "GVAX Cell Genesys", Current Opinion in Investigational Drugs, 2(6):844-848 (2001).			
	BT	Fearon, et al., Interleukin-2 Production By Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response", Cell, 60:397-403 (1990).			
	BU	Golumbek, et al., "Treatment of Established Renal Cancer By Tumor Cells Engineered to Secrete Interleukin-4", Science, 254:713-716 (1991).			
	BV	Gansbacher, et al., "Interleukin 2 Gene Transfer Into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity", J. Exp. Med., 172:1217-1224 (1990).			
	BW	Gansbacher, et al., "Retroviral Vector-Mediated γ -Interferon Gene Transfer Into Tumor Cells Generates Potent and Long Lasting Antitumor Immunity", Cancer Res., 50:7820-7825 (1990).			
	BX	Gri, et al., "OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes With GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response", J. Immunol., 170: 99-106 (2003).			
	BY	Hock et al., (erroneously listed in Spec as "Columbo"), "Interleukin 7 Induces CD4+ T Cell-Dependent Tumor Rejection", J. Exp. Med., 174:1291-1298 (1991)			
	BZ	Hom, et al., "Common Expression of Melanoma Tumor-Associated Antigens Recognized By Human Tumor Infiltrating Lymphocytes: Analysis By Human Lymphocyte Antigen Restriction", Journal of Immunother., 10(3): 153-164 (1991).			
	CA	Huebner, et al., "The Human Gene Encoding GM-CSF Is at 5q21-q32, the Chromosome Region Deleted in the 5q- Anomaly, Science 230:1282-1285 (1985).			
	CB	Jaffee, et al., "Gene Therapy: Its Potential Applications in the Treatment of Renal-Cell Carcinoma", Seminars in Oncology, 22(1):81-91 (1995).			
	CC	Jaffee, et al., "Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine For Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation", Journal of Clinical Oncology, 19(1):145-156 (2001).			
	CD	Kawakami, et al., "Shared Human Melanoma Antigens: Recognition By Tumor-Infiltrating Lymphocytes in HLA-A2.1-Transfected Melanomas", J. Immunol., 148(2): 638-643 (1992).			
	CE	Klein, et al., "Properties of the K562 Cell Line, Derived From a Patient With Chronic Myeloid Leukemia", Int. J. Cancer, 18:421-431 (1976).			
	CF	Kwon, et al., "Expression Characteristics of Two Potential T Cell Mediator Genes", Cell Immunol., 121:414-422 (1989).			
JO	CG	Kwon, et al., "cDNA Sequences of Two Inducible T-Cell Genes", Proc. Natl. Acad. Sci. USA, 86:1963-1967 (1989).			
EXAMINER		Ila Anpeshi		DATE CONSIDERED 6/18/06	
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 3802-090-27 CIP	SERIAL NO. 10/807,449
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Karin JOOSS et al.		FILING DATE March 24, 2004	
		GROUP ART UNIT 1632			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
JO	CH	Lee, et al., "Genetic Immunotherapy of Established Tumors With Adenovirus-Murine Granulocyte-Macrophage Colony-Stimulating Factor", Human Gene Therapy, 8:187-193 (1997).			
	CI	Lozzio, et al., "Human Chronic Myelogenous Leukemia Cell-Line With Positive Philadelphia Chromosome", Blood, 45(3):321-334 (1975).			
	CJ	Melero, et al., "Monoclonal Antibodies Against the 4-1BB T-Cell Activation Molecule Eradicate Established Tumors", Nature Medicine 3(6):682-685 (1997).			
	CK	Nagai, et al., "Irradiated Tumor Cells Adenovirally Engineered to Secrete Granulocyte/Macrophage-Colony-Stimulating Factor Established Antitumor Immunity and Eliminate Pre-Existing Tumors in Syngeneic Mice", Cancer Immunol. Immunother., 47:72-80 (1998).			
	CL	Plaksin, et al., "Effective Anti-Metastatic Melanoma Vaccination With Tumor Cells Transfected With MHC Genes and/or Infected With Newcastle Disease Virus (NDV)", Int. J. Cancer, 59:796-801 (1994).			
	CM	Porgador, et al., "Immunotherapy of Tumor Metastasis Via Gene Therapy", Nat. Immun. 13:113-130 (1994).			
	CN	Salgia, et al., "Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-Small-Cell Lung Carcinoma", Journal of Clinical Oncology, 21(4): 624-630 (2003).			
	CO	Salvadori, et al., "B7-1 Amplifies the Response to Interleukin-2-Secreting Tumor Vaccines <i>In Vivo</i> , but Fails to Induce a Response By Naive Cells <i>In Vitro</i> ", Hum. Gene Ther., 6:1299-1306 (1995).			
	CP	Shuford, et al., "4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification <i>In Vivo</i> of Cytotoxic T Cell Responses", J. Exp. Med., 186(1):47-55 (1997).			
	CQ	Simons, et al., "Induction of Immunity to Prostate Cancer Antigens: Results of a Clinical Trial of Vaccination With Irradiated Autologous Prostate Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Using <i>ex vivo</i> Gene Transfer", Cancer Res., 59:5160-5168 (1999).			
	CR	Simons, et al., "Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated By <i>ex vivo</i> Granulocyte-Macrophage Colony-Stimulating Factor Gene Transfer", Cancer Res., 57:1537-1546 (1997).			
	CS	Soiffer, et al., "Vaccination With Irradiated Autologous Melanoma Cells Engineered to Secrete Human Granulocyte-Macrophage Colony-Stimulating Factor Generates Potent Antitumor Immunity in Patients With Metastatic Melanoma", Proc. Nat'l. Acad. Sci. USA, 95:13141-13146 (1998).			
	CT	Teng, et al. "Long-Term Inhibition of Tumor Growth By Tumor Necrosis Factor in the Absence of Cachexia or T-Cell Immunity", Proc. Nat'l. Acad. Sci. USA, 88:3535-3539 (1991).			
	CU	Vane, et al., "Cyclooxygenases 1 and 2", Annu. Rev. Pharmacol. Toxicol., 38:97-120 (1998).			
	CV	Weinberg et al., "Engagement of the OX-40 Receptor <i>In Vivo</i> Enhances Antitumor Immunity", The Journal of Immunology, 164, 2160-2169 (2000).			
JO	CW	Armstrong, Ph.D., T., et al., "Cytokine Modified Tumor Vaccines", Surg. Oncol. Clin. N. Am., 11, 681-696 (2002).			
EXAMINER		Ilan Asperski		DATE CONSIDERED 6/18/06	
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					


Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 3802-090-27 CIP	SERIAL NO. 10/807,449
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Karin JOOSS et al.			
		FILING DATE March 24, 2004		GROUP ART UNIT 1632	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
JO	CX	Altschul, S., et al., "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs", Nucleic Acids Res., Vol. 25, 17, 3389-3402 (1997).			
	CY	Altschul, S., et al., "Basic Local Alignment Search Tool", J. Mol. Biol. 215, 403-410 (1990).			
	CZ	Asher, A., et al., "Murine Tumor Cells Transduced With The Gene For Tumor Necrosis Factor- α /Evidence for Paracrine Immune Effects of Tumor Necrosis Factor Against Tumors", J. Immunol., 146, 3227-3234 (1991).			
	DA	Ausubel, F., et al., "Current Protocols In Molecular Biology", Vol. 1-3, 1987 Editions.			
	DB	Bergers, G., et al., "Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice", Science, 284, 808-812 (1999).			
	DC	Berkelhammer, J., et al., "Development Of A New Melanoma Model In C57BL/6 Mice", Cancer Res., 42, 3157-3163 (1982).			
	DD	Bodey, B., et al., "Failure of Cancer Vaccines: The Significant Limitations Of This Approach To Immunotherapy", Anticancer Res., 20, 2665-2676 (2000).			
	DE	Bour-Jordan, H., et al., "CTLA-4 Regulates The Requirement For Cytokine-Induced Signals in T _H 2 Lineage Commitment", Nature Immunol., 4, 2, 182-188 (2003).			
	DF	Freshney, R., "Animal Cell Culture, A Practical Approach" IRL Press, 1987 Edition.			
	DG	Griswold, D., "Consideration Of The Subcutaneously Implanted B16 Melanoma As A Screening Model For Potential Anticancer Agents", Cancer Chemo. Reports, Part 2, Vol. 3, No. 1, 315-324 (1972).			
	DH	Guo, Z., et al., "Evaluation of Promoter Strength for Hepatic Gene Expression In Vivo Following Adenovirus-Mediated Gene Transfer", Gene Therapy, 3, 802-810 (1996).			
	DI	Havell, E., et al., "The Antitumor Function of Tumor Necrosis Factor (TNF)", J. Exp. Med., 167, 1067-1085 (1988).			
	DJ	Hock, H., et al., "Interleukin 7 Induces CD4+ T Cell-Dependent Tumor Rejection", J. Exp. Med. 174, 1291-1298 (1991).			
	DK	Hu, H-M., et al., "Development of Antitumor Immune Responses in Reconstituted Lymphopenic Hosts", Cancer Res., 62, 3914-3919 (2002).			
	DL	Huang, A., et al., "Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens", Science, 264, 961-965 (1994).			
	DM	Ill, C., et al., "Optimization of the Human Factor VIII Complementary DNA Expression Plasmid For Gene Therapy of Hemophilia A", Blood Coagulation and Fibrinolysis, Vol. 8, 2, S23-S30 (1997).			
JO	DN	Kim, D., et al., "Use of the Human Elongation Factor 1 α Promoter As A Versatile and Efficient Expression System", Gene, 91, 217-223 (1990).			
EXAMINER		Elia Orpelusli		DATE CONSIDERED 5/18/06	
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 3802-090-27 CIP	SERIAL NO. 10/807,449
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Karin JOOSS et al.			
		FILING DATE March 24, 2004		GROUP ART UNIT 1632	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
JO	DO	Kim, T-Y, et al., "Both E7 and CpG-Oligodeoxynucleotide Are Required for Protective Immunity Against Challenge With Human Papillomavirus 16 (E6/E7) Immortalized Tumor Cells: Involvement of CD4+ and CD8+ T Cells in Protection", Cancer Res., 62, 24, 7234-7240 (2002).			
	DP	Kuroda, E., et al., "Sensitivity Difference to the Suppressive Effect of Prostaglandin E ₂ Among Mouse Strains: A Possible Mechanism to Polarize Th2 Type Response in BALB/c Mice", J. Immunol., 164, 2386-2395 (2000).			
	DQ	Mao, J., et al., "Celecoxib Modulates the Capacity for Prostaglandin E ₂ and Interleukin-10 Production in Alveolar Macrophages from Active Smokers", Clinical Cancer Research, Vol. 9, 5825-5841 (2003).			
	DR	Oettgen, H., et al., "The History of Cancer Immunotherapy", Biologic Therapy of Cancer, Ch. 6, 87-119 (1991).			
	DS	Remington's Pharmaceutical Sciences, 15th Edition, 1035-1038 & 1570-1580 (1975).			
	DT	Rivera, V., et al., "A Humanized System for Pharmacologic Control of Gene Expression", Nature Medicine, Vol. 2, 9, 1028-1032 (1996).			
	DU	Sambrook, J., et al., "Molecular Cloning A Laboratory Manual", 2nd Edition, Cold Spring Harbor Laboratory Press, Vol. 1 (1989).			
	DV	Samulski, R., et al., J. Virology, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", Vol. 63, 9, 3822-3828 (1989).			
	DW	Sawyer, T., et al., "Src Homology-2 Inhibitors: Peptidomimetic and Nonpeptide", Mini Reviews in Medicinal Chemistry, 2, 475-488 (2002).			
	DX	Sharma, S., et al., "Tumor Cyclooxygenase 2-dependent Suppression of Dendritic Cell Function", Clinical Cancer Research, Vol. 9, 961-968 (2003).			
JO	DY	Ye, X., et al., "Regulated Delivery of Therapeutic Proteins After In Vivo Somatic Cell Gene Transfer", Science, 283, 88-91 (1999).			
	DZ				
	EA				
	EB				
	EC				
	ED				
	EE				
	EF				
	EG				
EXAMINER		Ileana Ouspenski		DATE CONSIDERED 6/18/06	
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

Form PTO 1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 3802-090-27 CIP		SERIAL NO. 10/807,449	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Karin JOOSS, et al.			
		FILING DATE March 24, 2004		GROUP ART UNIT 1632	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
JO	AA	2004/0121300	06/24/04	FREY, et al.			
	AB	2002/0037282	03/28/02	LEVITSKY, et al.			
	AC						
	AD						
	AE						
	AF						
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO			
	AK						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AP	Armitage, "Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor", Blood, Vol. 92, No. 12, pp. 4491-4508, 1998.					
	AQ	Armstrong, et al., "Antitumor Effects of Granulocyte-Macrophage Colony-Stimulating Factor Production by Melanoma Cells", Cancer Research, Vol. 56, pp. 2191-2198, 1996.					
	AR	Dong, et al., "Angiostatin-mediated Suppression of Cancer Metastases by Primary Neoplasms Engineered to Produce Granulocyte/Macrophage Colony-stimulating Factor", Jour. Exp. Med., Vol. 188, No. 4, pp. 755-763, 1998.					
	AS	Emens, et al., "Chemotherapy: Friend or foe to cancer vaccines?", Current Opinion in Molecular Therapeutics, Vol. 3, No. 1, pp. 77-84, 2001.					
JO	AT	Jaffee, et al., "Use of Murine Models of Cytokine-Secreting Tumor Vaccines to Study Feasibility and Toxicity Issues Critical to Designing Clinical Trials", Jour. of Immunotherapy, Vol. 18, No. 1, pp. 1-9, 1995.					
EXAMINER <i>Ilia Ouspenski</i>				DATE CONSIDERED <i>6/18/06</i>			

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Based on PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Substitute for form 449A/PTO
& TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/807,449
Filing Date	March 24, 2004
First Named Inventor	Karin JOOSS
Art Unit	1644
Examiner Name	Ilia Ouspenski
Attorney Docket Number	3802-090-27 CIP

Sheet 1 of 1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JO		US-5,891,432	04-06-99	HOO	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

Examiner Signature	Ilia Ouspenski	Date Considered	6/18/06
--------------------	----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.